News explainer
Saxenda is being discontinued in the US, with last shipments to wholesalers in late January 2027
Key numbers
- Result
- Last Saxenda shipments to US wholesalers take place in late January 2027.
- Date
- Notice read on Nov 20, 2026 on Novo Nordisk's prescriber site. The page does not give the date it was first posted.
- Announced by
- Novo Nordisk: Novo Nordisk discontinuation notice
- Note
- Novo says the decision "is not the result of any safety or quality-related concerns."

What happened
Novo Nordisk's prescriber site carries an advance notice: "we will be discontinuing Saxenda® in the US, with last shipments to wholesalers taking place in late January 2027" (Novo Nordisk).
Novo gives the reason plainly: more FDA-approved treatment options have become available and the number of people using Saxenda has kept falling, so it made a portfolio decision to discontinue the brand. It says the decision is not about safety or quality, and asks prescribers to talk with patients about alternative treatments.
Saxenda (liraglutide) is a daily injection. The newer options include weekly injections such as Wegovy and Zepbound and daily pills such as the Wegovy pill and Foundayo. Our Saxenda guide covers the switch in more detail.
What this means for cost
If you are moving off Saxenda, these are today's prices on our records for the main options. Your prescriber chooses the drug and the strength.
| Option | Cash price on our record | Read |
|---|---|---|
| Wegovy (semaglutide), Novo Nordisk | Pen: $199 a month for the first 2 fills at 0.25 mg or 0.5 mg for new patients, through December 31, 2026, then $349. Pill: $149 at 1.5 mg, $199 at 4 mg, $299 at 9 mg and 25 mg. | Maker's page, Nov 6, 2026 |
| Foundayo (orforglipron), Eli Lilly | Through LillyDirect: from $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 at higher doses. | Maker's page, Nov 6, 2026 |
| Zepbound (tirzepatide), Eli Lilly | KwikPen through LillyDirect: from $299 a month at 2.5 mg, $399 at 5 mg, $449 at higher doses. | Maker's page, Nov 6, 2026 |
| EmbodyCompounded semaglutide | $79/mo, medication plus recorded program fee | Recorded Nov 6, 2026 |
| CoreAge RxCompounded semaglutide | $79/mo, medication plus recorded program fee | Recorded Nov 6, 2026 |
| AgelessRxCompounded semaglutide | $139/mo, medication plus recorded program fee | Date not recorded |
| EmbodyCompounded tirzepatide | $129/mo, medication plus recorded program fee | Recorded Nov 6, 2026 |
| CoreAge RxCompounded tirzepatide | $129/mo, medication plus recorded program fee | Recorded Nov 6, 2026 |
| Sprout HealthCompounded tirzepatide | $199 per 4 weeks, medication plus recorded program fee | Recorded Nov 6, 2026 |
Compounded rows are the lowest recorded monthly subtotals among active listings, sorted by price: medication plus any recorded program fee, with other costs such as labs or shipping not included. Compounded medications are not FDA-approved and are not the brand products. Your prescriber decides which drug and strength fit you.
What happens next
Now to late January 2027
Pharmacies keep filling Saxenda from wholesaler stock. A good time to plan a switch with your prescriber.
Late January 2027
Last shipments to US wholesalers. After that, supply depends on what pharmacies still hold.
Sources
- Novo Nordisk, Saxenda prescriber site, discontinuation notice, read Nov 20, 2026